导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.29% | 3462/4773 |
| 近一周 | -1.68% | 3107/5467 |
| 近一月 | -4.44% | 1728/5421 |
| 近一季 | -4.33% | 1593/5238 |
| 近半年 | -4.60% | 2976/4931 |
| 近一年 | -8.00% | 3243/4400 |
| 近两年 | 35.97% | 2063/2954 |
| 近三年 | 25.96% | 1249/2253 |
| 成立以来 | 24.76% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.54% 3862/4961 |
1.86% 2983/5312 |
- - |
- - |
| 2025 | 23.90% 1831/4813 |
7.47% 496/3635 |
2.32% 1647/4076 |
15.93% 2754/4524 |
-2.81% 3211/4813 |
| 2024 | 16.51% 799/3463 |
0.25% 1012/2808 |
3.54% 266/3014 |
15.07% 1824/3129 |
-2.45% 2089/3463 |
| 2023 | -9.88% 1242/2656 |
2.42% 1353/2280 |
-2.76% 655/2385 |
-4.91% 1254/2515 |
-4.84% 1192/2655 |
| 2022 | -13.90% 347/2207 |
-11.55% 527/1919 |
7.11% 531/2016 |
-14.73% 1138/2113 |
6.58% 358/2208 |
| 2021 | -8.79% 1058/1822 |
0.34% 301/1255 |
1.62% 1041/1330 |
-9.40% 1177/1466 |
-1.26% 1345/1822 |
| 2020 | - - |
- - |
11.94% 708/1067 |
5.95% 886/1164 |
14.44% 276/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大成中华沪深港300指数(LOF)C VS. 长安沪深300非周期A(740101) |